Paraneoplastic sensorimotor polyneuropathy in prostatic adenocarcinoma: A case report

Medicine (Baltimore). 2018 Apr;97(15):e0030. doi: 10.1097/MD.0000000000010030.

Abstract

Rationale: Paraneoplastic syndrome is a very rare syndrome among prostate cancer patients. In particular, paraneoplastic sensorimotor neuropathy has never been reported as a complication of prostatic adenocarcinoma.

Patient concerns: A 75-year-old man who was diagnosed with prostatic adenocarcinoma with multiple metastases received cancer treatment. But, numbness and tingling sensations in both sides of the upper and lower limbs got progressively worse.

Diagnosese: He was diagnosed with positive anti-Hu antibodies paraneoplastic sensorimotor polyneuropathy caused by prostatic adenocarcinoma.

Interventions: The patient received physical therapy, occupational therapy, and opioid medication during 3 weeks at cancer rehabilitation department during 3 weeks.

Outcomes: There was no improvement in functional outcome in this patient. But, the patient's neuropathic pain was improved by the use of opioid agents.

Lessons: This case report is the first to report anti-Hu antibody-positive paraneoplastic sensorimotor neuropathy in a patient with adenocarcinoma of the prostate.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma* / complications
  • Adenocarcinoma* / pathology
  • Adenocarcinoma* / therapy
  • Aged
  • Analgesics, Opioid / administration & dosage*
  • Antineoplastic Protocols
  • Autoantibodies / blood*
  • ELAV Proteins / immunology*
  • Extremities* / innervation
  • Extremities* / physiopathology
  • Feedback, Sensory
  • Humans
  • Male
  • Neoplasm Staging
  • Paraneoplastic Polyneuropathy* / blood
  • Paraneoplastic Polyneuropathy* / etiology
  • Paraneoplastic Polyneuropathy* / physiopathology
  • Paraneoplastic Polyneuropathy* / therapy
  • Physical Therapy Modalities*
  • Prostatic Neoplasms* / complications
  • Prostatic Neoplasms* / pathology
  • Prostatic Neoplasms* / therapy
  • Treatment Outcome

Substances

  • Analgesics, Opioid
  • Autoantibodies
  • ELAV Proteins